FDA Approves Afrezza Inhaled Insulin for Ages 6+ Based on INHALE-1 Trial

The June 2026 approval expands adult labeling to pediatrics, allowing Technosphere insulin powder delivered via inhaler at the start of meals rather than 15-20 minutes prior. INHALE-1 randomized 230 participants aged 6-17 and met its primary endpoint of non-inferior HbA1c change versus subcutaneous insulin aspart at 26 weeks, with similar rates of hypoglycemia and no new pulmonary safety signals in spirometry follow-up.

Existing coverage frames the decision as a simple convenience win, yet overlooks documented barriers: patients must pass baseline FEV1 screening and annual lung-function monitoring, which excludes roughly 10-15% of candidates with asthma or reduced pulmonary reserve common in youth with diabetes. Reimbursement remains fragmented; commercial plans often require prior authorization and step therapy through multiple daily injections, limiting real-world uptake.

Longer-term data from adult post-marketing registries show adherence gains of 20-25% versus pens in motivated cohorts, but pediatric persistence will hinge on school policies permitting inhaler use and on out-of-pocket costs that currently exceed $300 monthly without robust copay assistance. Next, MannKind must complete the ongoing 52-week extension of INHALE-1 and generate payer-specific health-economic models to support formulary inclusion.